After serving as the director of the National Human Genome Research Institute for more than 15 years, Eric Green has left his role.
The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Owen Witte with the twelfth annual Harrington Prize for Innovation in Medicine.
Matthew J. Carpenter was named associate director of the Cancer Prevention & Control Research Program at MUSC Hollings Cancer Center.
Physician-scientist Theodore Scott Nowicki, an assistant professor-in-residence of pediatric hematology/oncology and microbiology, immunology, and molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded a $4.5 million R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors.
A University of Arizona Mel and Enid Zuckerman College of Public Health researcher has received a $1.2 million grant from the American Cancer Society to evaluate potential links between the neighborhood environment and cancer risk.
Nemours Children’s Health opened the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, on March 19. The institute is a state-of-the-art facility for pediatric patients in the Delaware Valley and beyond.
A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.
A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.
AbbVie announced the final analysis of the confirmatory phase III MIRASOL trial evaluating the efficacy and safety of Elahere in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy.
Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels.
